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Abstract 
Advances in nanotechnology have enabled solutions for challenging drug delivery targets. 
While the eye presents numerous emerging opportunities for delivery, analysis and sensing; 
issues persist for conventional applications. This includes liquid phase formulation 
localisation on the ocular surface once administered as formulated eye-drops; with the vast 
majority of dosage (>90%) escaping from the administered site due to tear production and 
various drainage mechanisms. The work presented here demonstrates a single needle 
electrohydrodynamic (EHD) engineering process to nano-coat (as an on demand and 
controllable fiber depositing method) the surface of multiple contact lenses rendering 
formulations to be stationary on the lens and at the bio-interface. The coating process was 
operational based on ejected droplet charge and glaucoma drug timolol maleate (TM) was 
used to demonstrate surface coating optimisation, bio-surface permeation properties (flux, 
using a bovine model) and various kinetic models thereafter. Polymers PVP, PNIPAM and 
PVP:PNIPAM (50:50 %w/w) were used to encapsulate the active. Nano-fibrous and 
particulate samples were characterised using SEM, FTIR, DSC and TGA to confirm structural 
and thermal stability of surface coated formulations. More than 52% of nano-structured 
coatings (for all formulations) were <200nm in diameter. In vitro studies show coatings to 
exhibit biphasic release profiles; an initial burst release followed by sustained release; with 
TM-loaded PNIPAM coating releasing most drug after 24 hours (89.8%). Kinetic modelling 
(Higuchi, Korsmeyer-Peppas) was indicative of quasi-Fickian diffusion whilst biological 
evaluation demonstrates adequate ocular tolerability. Results from permeation studies 
indicate coated lenses are ideal to reduce dosing regimen, which in turn will reduce 
systemic drug absorption. Florescent microscopy demonstrated probe and probe embedded 
coating behaviour from lens surface in vitro. The multiple lens surface coating method 
demonstrates sustained drug release yielding promising results; suggesting both novel 
device and method to enhance drug activity at the eyes surface which will reduce 
formulation drainage. 
Key Words: contact lens, fiber, drug delivery, timolol maleate, electrospinning, glaucoma  
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Introduction 
Glaucoma is the 2nd leading cause of blindness in the world; affecting 2% of the worlds’ 
population over 40 years of age [1]. It is a progressive multifactorial optic neuropathy, often 
resulting in vision loss due to heightened elevation in ocular pressure (OP). The increase in 
OP is a result of insufficient drainage of the aqueous humour (AH); (a transparent gel 
produced by the ciliary body in the eye which occupies the space between the cornea and 
lens). The reduction in removal of AH is due to anatomical changes in the trabecular 
meshwork. Here, the tubes which remove AH from the eye to the bloodstream are damaged 
which consequently lead to impairment of retinal nerves and the optic nerve [2]. At present, 
there is no cure for glaucoma and there is an urgent need to enhance the quality of life for 
patients and those currently on life-long treatment. Many of these regimens often require 
multiple dosing of active throughout the day. 
Treatment of glaucoma is usually in the form of eye drops, a dosage form that makes up 
approximately 90% of all ocular formulations [3]. They are classed into those that reduce AH 
production (beta blockers, alpha agonists, carbonic anhydrase inhibitors) and those that 
improve the drainage of AH (prostaglandin analogues, cholinergics). Timolol (a beta 
adrenergic blocking agent) blocks the action of the sympathetic nervous system by 
competing with adrenergic neurotransmitters [4]. For the treatment of glaucoma, beta 
blockers like Timolol work by blocking the receptors in the ciliary body; reducing AH 
production [2]. However, Timolol also has an adverse effect on the cardiac and pulmonary 
system. If Timolol is present in the blood stream over a specific threshold concentration, it 
can slow down the heart rate, decrease blood pressure and reduce the function of the 
lungs, which can cause more inconveniences for the patient [4]. 
Despite ease of formulation and patient compliance, there are limitations with regards to 
the use of eye drops including nasolacrimal drainage and inability to control drug release 
leading to less than 5% of drug permeating through the cornea to targeting tissue; the ciliary 
body for glaucoma [5]. The biggest limitation is poor drug bioavailability as a result of short 
residence time in the eye. Consequently, to reach the therapeutic concentration in the eye, 
a higher dose of the drug needs to be administered [6]. Addressing these limitations has led 
to research being directed at the potential of various ocular devices; the most common 
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being soft contact lenses [7]. Contact lenses (CLs) are becoming increasingly common; 
replacing glasses for vision correction. However, recent developments have extended the 
use of CLs for cosmetics and therapeutics. The concept of using CLs as drug delivery devices 
was first introduced in the 1960’s [8] but only in the last 2 decades have CLs been 
considered as useful ocular devices for delivery of drugs such as antibiotics [9], non-
steroidal anti-inflammatory drugs (NSAIDs) [10], and anti-glaucoma actives [11,12]. Timolol 
(more specifically the maleate salt of Timolol (TM)) has been extensively used to assess the 
feasibility of CLs as drug delivery devices, with promising conclusions [13-15]. 
Many concepts, conventional and novel, to alter CLs and exploit the properties (e.g. the 
hydrophilicity [16]) of common hydrogel (HG) materials have been introduced to achieve 
sustained ocular drug delivery. Such notions include the simplicity of soaking lenses in a 
drug solution with consequent drug uptake in post-lens region (soak and release) [17] whilst 
more complex methods include molecular imprinting on HG matrix [18] or modifying the 
composition of the HG matrix [12].  Other methods involve embedding colloidal carriers 
(nanoparticles (NPs) [14], micelles [19]) within the HG matrix in an attempt to retard 
diffusion. 
Electrohydrodynamic atomisation (EHDA) is a one-step deposition and an on demand 
method to coat biomaterials and is extendable to CLs. The principle revolves around using 
electrical forces to atomise liquids for the generation of nano and micrometre structures 
suitable for drug delivery. The fundamentals of this process are based on two vital 
processing parameters; applied voltage and flow rate. Various physical properties (viscosity, 
density and surface tension) also influence the resulting size and morphologies of the 
structures produced.  This process is a versatile technique with great potential for enhancing 
bio-interfaces [20]. A large array of materials including temperature and stress sensitive 
active pharmaceutical ingredients (APIs)/materials (e.g. proteins and genes[21,22]) have 
been utilised to demonstrate the application of EHDA.  Based on the choice of materials, it is 
possible to alter the release of drug when needed; in a controlled manner over minutes, 
hours or even days. 
Since ocular formulation (liquid phase eye-drops) administration suffers loss from extensive 
drainage and tear forming mechanisms, the aim of this study was to develop an on demand 
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nano-structured multiple lens coating process; enabling greater formulation stability on lens 
surface and at the bio-interface. Polymers polyvinylpyrrolidone (PVP) and poly (N-
isopropylacrylamide) (PNIPAM) were selected alongside glaucoma drug Timolol Maleate 
(TM) to optimise the multi-lens EHDA coating process. Formulation stability in matrix form 
was assessed using several techniques and the permeation (diffusive flux) across the bio-
interface (cornea) was determined. In vitro release data was used to determine ideal kinetic 
models for TM release from various nano-structured systems on the lens coating. 
Fluorescent microscopy was also used to determine surface behaviour of both probe and 
probe-embedded lens coating in vitro.  
Materials and Methods 
Materials 
PVP (4.4 x104 g/mol) was obtained from Ashland, UK. Methanol, PNIPAM (2-4x104 g/mol) 
timolol maleate (TM, ≥98%), acetone, sodium hydroxide and Rhodamine B were supplied by 
Sigma Aldrich, Dorset, UK. PureVision® (Balafilcon A) silicone hydrogel contact lenses 
manufactured by Bausch and Lomb (New York, USA) were utilised in this study.  All reagents 
were of the analytical grade.  
Solution Preparation 
Polymeric solutions (selected polymer, or composite systems, at 5%w/v) containing TM (5% 
w/w of polymer) were prepared using methanol as the solvent by magnetic stirring for 10 
minutes at ambient temperature (23°C). Table 1 shows the composition of each formulation 
used.  
Coating Application 
A syringe containing 5mL of solution was attached to a syringe infusion pump (Harvard 
Apparatus, Pump 11-Elite, USA) which controlled the flow rate of polymer-drug solution. 
The solution was passed through silicone tubing which was connected to a stainless steel 
coaxial needle device (only single needle was utilised here, inner diameter 1.6mm) at 
various flow rates (5, 10 and 15 µL/min). The device was attached to a high power voltage 
supply (Glassman High Voltage Supply, UK). The electrically driven spraying process was 
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carried out at ambient temperature (23°C).  Jetting mode-maps were constructed by varying 
the flow rate to optimise the processing parameters of the atomising system (Figure 1a).  
Atomised coatings were deposited on microscope slides for preliminary analysis and 
subsequently onto commercial contact lenses. Pure Vision lenses were used in this study. 
For controlled deposition via atomised coatings, a lens holder device (accommodating up to 
4 lenses) was built (Figure 1b and 1c), hosting ground electrodes, which enabled deposition 
onto peripheral regions of lenses whilst keeping the central regions un-coated (for sight). 
The lenses were weighted before and after to ascertain the mass of each coating. An 
illustration of the process mechanism is provided in Figure 1d. Exploratory experiments 
were performed to determine the spraying distance; as this is crucial in ensuring particle or 
fiber formation for thin film engineering. 
Particle Coating Characterisation/analysis 
Imaging 
For preliminary studies coated microscope slides were analysed in detail using Scanning 
Electron Microscopy (SEM) to assess morphology of particle coatings. Prior to analysis, 
samples were gold coated (S150B, Edwards, Crawley, West Sussex, UK) under vacuum and 
images were obtained using a Zeiss Evo HD-15 (using an accelerating voltage of 5kV).  
Working distances between 9.5 and 10.5mm were utilised while applied voltages ranged 
from 10 to 18kV with magnifications of 5k and 50k; termed as low and high magnifications. 
Based on these results, the samples with the optimum conditions (uniform structures and 
near mono-dispersed particles) were further examined. These images were analysed using 
Smart Tiff software to obtain particle size distribution data.  The optimised samples were 
observed at low magnification (x40) using Leica DME Optical Microscope using XL1 Camera 
Software. Digital images of uncoated and coated lenses with variable coating thickness were 
captured using a Samsung NX2000 Mirrorless digital Camera. Coating density was further 
confirmed using a Leica Model DM E-optical microscope. Probe encapsulation within 
engineered polymer particles was demonstrated using an EVOS Fluorescence Microscope at 
x40 magnification.  
Thermal Analysis 
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The thermal properties of polymeric coating were analysed using Differential Scanning 
Calorimetry (DSC) and Thermogravimetric Analysis (TGA). DSC analysis was carried out using 
a Jade differential scanning calorimeter (Perkin Elmer, US). The temperature scale of the 
DSC instrument was calibrated using indium as a standard; which has a known melting point 
of 156.6°C. Sealed pans containing 2-4mg of sample were heated under a flow of nitrogen 
gas at a rate of 20°C/min from 20 to 300°C. TGA analysis was carried out using Pyris 1 TGA 
thermogravimetric analyser (Perkin Elmer, US). Under the flow of nitrogen gas and air, 
sealed pans containing 8-10mg of sample were heated at a rate of 20°C/min from 20 to 
700°C. 
FTIR Spectroscopy 
Potential interactions between drug (TM) and polymer were studied using Fourier 
Transform Infrared Spectroscopy (FTIR). Atomised samples, as well as neat materials, were 
scanned over the range 400-4000cm-1 using FTIR Platinum-ATR fitted with Bruker Alpha 
Opus 27 FT-IR at an average of 10 scans at resolution 4cm
-1
 at ambient temperature.  
Contact Angle Analysis 
Contact angle of the atomised structures were characterised using a ThetaLite TL100 
contact angle goniometer; with data analysed using OneAttension software. 10µl distilled 
water droplets were used. Each sample was analysed 5 times in Sessile Drop mode and an 
average was obtained.  
In vitro drug release studies 
A lens holder was designed (for coated lenses) to enable surface contact between lens and 
the release medium; phosphate buffer saline (PBS) pH=7.4. The coated lenses were fixed in 
the holder and the whole device was placed into vials containing 10mL of PBS (at 37°C) 
which was constantly stirred. At predetermined time intervals, the holder was removed and 
placed into fresh PBS vials at 37°C. This method has been adapted from Mehta et al [27].  
Drug release was determined using UV spectroscopy absorbance at λ=295nm.  Collated in 
vitro release data were plotted in various kinetic models to evaluate the release kinetics of 
TM from the polymeric coatings.  
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In vitro probe release with fluorescent analysis 
Using a similar set up described above for in vitro drug release, contact lenses were coated 
with various polymeric (PVP, PNIPAM, at 5%) and probe Rhodamine B (5 w/w% of polymer). 
The lenses were fixed into the lens holder and placed into vials of PBS at 37°C.  Five lenses 
were coated and exposed to PBS for each polymer system and were removed from the vials 
at predetermined times (0 mins, 10mins, 1 hr, 6 hrs and 24 hrs). Experiments were 
performed in triplicate for both polymers. Fluorescent microscopy was used to determine 
dye intensity on the lens and UV Spectroscopy (λ=560nm) was used to exhibit dye intensity 
(DI) in the release medium.  
Biological evaluation of TM-Loaded Nano-structures 
To assess the ocular tolerability of various formulations; a Bovine Corneal Opacity and 
Permeability (BCOP) test was carried out. The BCOP test is an evaluation of ocular irritation 
caused by the test formulation; specifically interference with the corneal integrity.  The 
three test samples were evaluated as well as normal saline for a negative control, sodium 
hydroxide (NaOH) as a positive control and acetone for mild positive control.   Freshly 
excised bovine eyes were assessed for any corneal damage and undamaged eyes were 
subsequently incubated for 10 minutes at 37±0.5°C in a water bath. One drop of normal 
saline solution was introduced to the bovine cornea, before further incubation (5 mins). 
100µL of the sample was administered onto the corneal surface and was left for 30 seconds. 
The bovine eye was washed with 10mL of normal saline and was incubated for an additional 
10 mins. Any corneal damage to the cornea was assessed visually by gauging the 
extent/degree of opacification sample was carried out as well as a staining method, using 
sodium fluorescein solution (2%w/v) under a cobalt blue light (465-490nm).   
Ex vivo corneal permeation of TM 
Corneal permeation of TM was assessed using Franz diffusion cells with diffusional surface 
area of 1.77cm2 (steps taken shown in Figure 1e). Freshly excised bovine eyes were 
evaluated for any damage before being carefully dissected to remove the entire cornea with 
a 2mm sclera ring to maintain cornea integrity. Cornea’s were rinsed with PBS and placed 
between the donor and receptor compartments, with the endothelium facing the receptor 
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compartment (which was filled with 12 mL PBS and a mini stirrer). The Franz cells were 
maintained at 35±0.5°C. $00µL of sample was removed at predetermined intervals and 
replaced with 400µL fresh PBS. UV spectroscopy (λ=295nm) was used to analyse samples. 
The cumulative amount of drug permeating through the cornea was plotted as a function of 
time. The slope of the linear portion of the graph was calculated. This rate of release was 
divided by the diffusional area to determine steady state flux, shown in Equation 1: 
                         =	
 	

      (Eq.1) 
Where Jss is steady state flux (µg.cm
-2
.h
-1
), dM/dt is the rate and A is the area available for 
diffusion. Apparent permeability coefficient was calculated by dividing flux by donor 
concentration of TM, as shown in Equation 2: 
      =      (Eq.2) 
Where Papp is the apparent permeability coefficient (cm
2
.s
-1
), Cd is the TM concentration in 
donor compartment.  
Statistical Analysis 
All experiments (unless stated otherwise) were carried out in triplicate. Statistical analysis 
(one-way analysis of variance, ANOVA) was performed. Differences in results between 
formulations were considered significant at a level of p<0.05.  
Results and Discussion 
In this study, PVP was used to demonstrate rapid drug release from a polymeric coating and 
encapsulation system. It is a common pharmaceutical excipient with good biocompatibility. 
PNIPAM is a biocompatible [23] temperature-sensitive polymer which undergoes reversible 
phase transition where it transforms from swollen state to dehydrated state (≥32°C). At 
physiological temperature, PNIPAM can expel its contents (losing up to ~90% of its original 
weight); rendering it useful in controlled drug delivery in the human body.  
Electrohydrodynamic atomisation of formulations  
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Figure 2 shows a conductive (no liquid, no applied voltage (Figure 2a)) needle/nozzle 
alongside formulation F1 in dripping mode which arises due to an incremental rise in 
applied voltage (Figure 2b). Stable EHDA jets for formulations are shown in Figures 2c-e (F1, 
F2 and F3, respectively). There are various EHDA spraying modes characterised based on 2 
principles; i) how the liquid jet leaves the conducting needle and ii) how the liquid jet breaks 
up. Dripping mode (Figure 2b) arises when fragments rather than droplet emerge from the 
needle. Jetting mode is observed when liquid breaks up into fine droplets, forming a stable 
Taylor cone (a prerequisite for controllable, near-uniform particle production) [24] at the 
nozzle exit, as seen in Figures 2c-e. Jetting mode-maps (Figure 2f-h) for each formulation 
show process optimisation windows at which stable jets are formed; ensuring production of 
near-monodispersed atomised droplets which undergo rapid drying to form nano-structures 
(particles, fibers or beaded fibers). Due to polymeric formulations possessing different 
physical liquid properties (based on selected polymer and solvent system), processing 
parameters (applied voltage, flow rate) need to be optimised to achieve samples of near-
monodispersed diameter size distribution. Each solution was subject to flow rates ranging 
from 0 to 20μL/min, to determine the optimum voltage using 1μL/min increments. With 
respect to formulations F1, F2 and F3, an applied voltage between 13 and 20kV sufficed for 
stable jet production, yielding atomised structures within the nano-meter range in the form 
of particle and beaded structures; all of which are characteristic of EHDA engineering. The 
deposition distance is an important factor in the EHDA process. Exploratory experiments 
were performed to determine an ideal deposition (needle tip to substrate) distance for 
particle engineering. This was determined to be 12cm. 
Imaging 
Figures 3a-c show images of uncoated and coated contact lenses. Figure 3a displays a blank, 
uncoated lens. Figures 3b and 3c display fine and coarse coatings, respectively. The density 
of coatings was also analysed using optical microscopy at x40 magnification as seen in 
Figures 3d-e. The presence and morphology of the resulting particles were identified using 
SEM at x5k and x50k magnification (Figures 3g-l). The most spherical, uniform particles were 
produced using F1 at a flow rate of 15µL/min. A comparison between stable formulation 
coating deposition show fibrous structures are obtained for F2 (10µL/min) and F3 
(10µL/min). The difference in structural morphology arises due to the increased viscosity of 
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parent formulations once PNIPAM was incorporated. The appearance of well-defined 
particles and fibres show the TM-loaded structures were essentially dry before depositing 
on the collection plate. This also suggests the vast majority of the vehicle (methanol) 
successfully evaporated from atomised formulations during the process. However, 
formulations F2 and F3 show collapsed/porous particles, although defined, indicating the 
evaporation rate of the solvent from the droplets (forming particles or fibers) to be rapid 
[25].  Figures 3m-o shows the entrapment of probe within the polymeric nano-structures. 
Figure 3m shows the encapsulation of Rhodamine B in PVP matrix, showing a green hue. 
Figures 3n and 3o correspond to the fluorescence images showing encapsulation of probe 
Rhodamine B. Fluorescence imaging demonstrated encapsulation of probe within nano-
structure polymeric matrix. Excitation of the C=O bond in PVP polymer emitted a longer 
wavelength (green). The conjugated double bonds within the ring structure in Rhodamine B 
induced red-shift in absorption when exposed to RFP. The composite structures appear 
yellow; demonstrating probe encapsulation within PVP nano-structures (Figure 3m). 
PNIPAM does not fluoresce; hence when overlaid with Rhodamine B micrographs under RFP 
a speckled effect is observed (Figure n). Figure 3o shows images for composite particles. 
Yellow structures can be seen due to the presence of PVP in the formulation.  
Particle and fiber size analysis 
Using Smart Tiff software, data was collated to reveal particle size distribution (PSD) of 
atomised structures. Figure 4 shows the PSD for formulations F1, F2 and F3, each signifying 
positively skewed data. . This indicates that more than ~50% of NPs produced were between 
1-200nm in diameter. The mean diameter was 183, 262 and 458nm for F1, F2 and F3, 
respectively. This increase in mean diameter is due to production of fibrous structures in 
formulations that contained PNIPAM. Increased solution viscosity leads to the generation of 
fibrous and spherical structures being produced, often termed beaded, which arise due to a 
transition between spraying (particles) and spinning (fibers). In this instance, mean 
diameters appear larger. Despite this, <2% of atomised particles were more than 1µm in 
diameter. These findings coincide with previous studies which used PVP as a polymeric 
matrix. Rasekh et al produced indomethacin-loaded PVP fibres with mean diameters of 
2.58±0.3µm for fabrication of wound dressings for transdermal drug delivery [26] whilst 
Mehta et al used PVP (low and high molecular weight) for coating ocular lenses using both 
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particles and fibres [27]. PNIPAM polymer engineering using EHDA is scarce. However, 
PNIPAM hydrogel particles have been yielded using aqueous precipitation polymerization. 
The particles here ranged between 550nm and 1.60µm; highlighting the potential of the 
current novel process; a technique useful for the production of smaller particles in a single 
step with direct deposition control. 
Thermal analysis 
When using emerging techniques within the pharmaceutical industry, it is imperative to 
ensure that the processing parameters do not significantly impact the stability of the active 
or excipients used. DSC was utilised to analyse the thermal transitions of raw materials 
compared to atomised nano-structures to ensure the solvent (methanol) and the EHDA 
process has not altered the physical structure of polymers; and subsequently the properties 
of the resulting nano-architectures.   The single, broad points present in the thermograms 
(Figure 5a) for raw materials correspond to each materials melting point. The DSC spectra 
for the electrically atomised samples also demonstrated similar endothermic peaks to each 
other with peaks at 115, 113 and 120°C for F1, F2 and F3, respectively. Here, it is noted that 
the melting point of the atomised formulations are lower than that of the raw 
drug/materials.  This is due to the increased distribution of TM (in the polymeric network) as 
a result of even molecular dispersion of drug throughout the polymeric matrix during the 
EHDA process compared to the drug in physical mixture.  The thermograms comprise of one 
peak for each formulation, demonstrating that the original structures of the raw materials 
was not compromised; highlighting the materials formed polymer-drug complexes and are 
acting as single system rather than individual components. The resulting DSC scan for F3 
particles show a lack of phase characteristic peaks of both PVP and PNIPAM as well as TM, 
except a broad peak with a maximum of 120°C, (a higher melting point than PVP and 
PNIPAM alone), suggesting a single, more stable system.  
To investigate the thermal behaviour of raw materials and the resultant structures, TGA was 
conducted. Figures 5bi and 5bii show TGA profiles for raw materials and atomised 
formulations.  The trace for raw TM depicts a sharp weight loss (75.14%) between 201°C 
and 370°C; shown as a significant decrease between this range. A decline as seen in Figure 
5bi) is characteristic of drug degradation, as found by Joshi et al [28]. Two major weight loss 
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events are observed with TGA profiles for both raw polymers. The first weight loss reduction 
is seen between 40°C and 140°C and between 40°C and 168°C for PVP (11.19% loss) and 
PNIPAM (3.8% loss) respectively; corresponding to initial moisture loss due to embedded 
water or residual solvent within the polymer. The second weight loss event is characteristic 
of polymeric thermal degradation. Within the temperature interval 390°C and 525°, a 
weight loss of 83.32% can be seen with the PVP TGA trace; where PVP thermally degrades 
by release of the pyrrolidone side group followed by decomposition on polyenic chains. 
These results coincide with earlier findings by Peniche et al. [29]. Thermal degradation of 
PNIPAM can be observed at 342-470°C; a weight loss of 93.18%. 
Figure 5bii shows the TGA thermograms of atomised formulations (nano-structures). The 
profile for all three samples is similar; all three formulations exhibit 2 major weight loss 
events between 20 and 120°C and between 370 and 485°C. The first weight loss occurrence 
corresponds to the dispelling of water and the second drastic weight loss is due to matrix 
polymer degradation. The composite structures degraded at a lower temperature compared 
to sole polymer-drug samples; which could is a result of polymeric chain arrangement 
during the EHDA process.  The presence of just two weight loss events for nano-structures 
suggests the polymers and the drug are acting as a single system rather than independent 
components. As with DSC, the shift at which temperature (or temperature range) product 
weight loss occurs also indicates drugs encapsulation, which has been previously 
demonstrated with other actives like indomethacin and naproxen [30].  
FTIR  
FTIR was performed on raw materials (as obtained powder form) and atomised structures 
(beaded and particles). The fingerprint of PVP and PNIPAM can be observed using FTIR; as 
seen in Figure 6 based on structural groups present. With respect to PVP, peaks at 3469cm-1 
and 1664cm
-1
 correspond to O-H stretching vibrations and C=O and N-C stretching vibration, 
respectively. Multiple peaks at 2948cm-1, 2918cm-1 and 2875cm-1 are present due to CH-CH2 
stretch vibration. Evidence of C-H deformation of cyclic CH2 groups can be seen at 1492cm
-1
, 
1459cm-1, 1419cm-1 and 1371cm-1. Amide III bond (C-N stretching vibration), amide V (CH2 
rocking vibrations) and amide IV bond are present at 1282cm
-1
, 732cm
-1
 and 648cm
-1
 
respectively. Characteristic absorption peaks on the PNIPAM spectra included amide II bond 
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at 1550cm-1, C=O stretching and CH3 asymmetric stretching vibrations at  1650cm
-1 and 
2970cm
-1 
,respectively.  
The stability of TM in presence of PVP and PNIPAM (separately and as composite) and 
following EHDA process can be assessed by analysing the drug-polymer interactions in the 
resulting spectra from FTIR spectroscopy. A broad band in the spectrum for TM corresponds 
to O-H/N-H stretching vibrations whilst peaks at 2968cm-1, 2891cm-1 and 2854cm-1 are 
present due to aliphatic C-H stretching vibration. The acid carbonyl group of maleic acid and 
the N-H bending vibrations show peaks at 1707cm-1 and 1496cm-1. Bands at 1229cm-1 and 
954cm
-1
 are due to O-H bending and hydroxyl C-O stretching vibrations, respectively. Similar 
peaks in the spectra for the atomised formulations indicate the chemical structure of TM 
was not compromised and was unaffected by the EHDA process.  
Contact Angle Analysis 
Contact angle (CA) is a quantitative measurement of the wetting of a solid by a liquid 
(usually water). Angles smaller than 90°C indicate high wettability whilst angles larger than 
90°C indicate poor wettability. The wettability of the surface of the electrically atomised 
samples were characterised and analysed over time (figure 7).  
Upon dropping the water droplet, the highest static CA was observed with beaded fibers 
produced by atomising F2 and F3 (130.1°C and 126.27°C, respectively). At t=0 seconds, the 
CA for TM-loaded PVP particles, an average CA of 83.02°C was recorded (figure 7d). This 
difference in initial CA between particles and fibers could be due to the surface roughness of 
the structures. The smooth surface of PVP particles (as confirmed through SEM) and high 
surface area of particles results in less air entrapment between the solid and liquid phases; 
ultimately resulting in a low static CA as soon as the water droplet comes into contact with 
the sample [31]. The water droplet applied to F2 samples completely decimated within 10 
seconds; indicating rapid penetration of water through the sample, dissolution of sample 
and/or the increase of degree of wettability with time (figure 7b). The CA for F1 and F3 
samples were unmeasurable after 10 minutes and 30 minutes respectively due to complete 
spreading of water after these time points. The polarity of PVP makes the polymer highly 
hydrophilic; indicating a low CA at t=0 seconds. However, the density of the samples can 
cause particles to agglomerate, trapping air between the particles. This may prevent the 
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water droplet penetrating and spreading. The dissolution of PVP over time allows the water 
penetrate the inter-particle pores and spread; with the droplet spreading completely within 
10 minutes of application [32]. The combination of particles and fibers with F3 samples 
increases the surface area and surface roughness of the sample; which in turn can 
contribute to the time it took for the CA to reduce from an average of 126°C at t=0 seconds 
to 0°C at t=1800 seconds.  
In vitro timolol release 
Evaluation of TM release from the atomised structures was carried using in vitro method. 
Figure 8 shows percentage cumulative release of TM from polymeric nano-structures in PBS 
at physiological conditions (pH=7.4, 37°C). The release study shows at t=1 minute; 25, 12.4 
and 11% TM was released from F1, F2 and F3 atomised formulations, respectively. At t= 30 
mins, over 50% of TM was released from all three atomised samples. At t = 24 hours, drug 
release was found to be 89.8% for F2, whereas for F1 and F3 formulations, only 63.2 and 
68.2% of TM was released, respectively. There is a noticeable general trend for all three 
formulations; similar release profiles can be observed. There is an initial burst release, 
followed by sustained, controlled release over time, eventually plateauing at t = 24 hours. 
The rapidly dissolving nature of PVP explains the initial rapid release seen with F1 and F3. 
Coatings with beaded morphology (i.e. F2 and F3) account for the initial rapid release 
observed as nano-structures tend to release drug more quickly due to higher surface area. 
PVP has been used often in ophthalmic formulations such as a rapidly dissolving matrix for 
the delivery of rifampicin[33] and in the manufacture of ocular films for delivery of anti-
inflammatory drug diclofenac sodium[34] which displayed controlled drug release showing 
more than 50% of drug to be released within 1 hour and the remaining drug released within 
4 hours[34]. Controlled release of drug using PNIPAM has been previously shown where the 
polymer has been used as a nano-vesicular carrier for anticancer drug 5-fluorouracil [35].  
Furthermore, an increase in physiological temperature exhibited sustained drug release 
with 35% of drug released within 24 hours.  The combination of a fast dissolving polymer 
(PVP) and a more sustained dissolving polymer (PNIPAM) along with the emerging EHDA can 
be used to develop polymeric device coatings with controlled and prolonged release, as 
shown by these in vitro studies. 
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Probe release 
To demonstrate drug leaving the polymer matrix at a sustained rate as well as the polymer 
remaining on the device, lenses were coated with atomised probe-loaded polymeric nano-
structures and exposed to PBS in similar fashion to in vitro TM release. Figure 9 displays the 
release profile of Rhodamine from the lens into PBS by showing both DI on the lens visually 
(fluorescence images) and DI in PBS, using UV-Spectroscopy. For PVP coated lenses, there is 
100% DI on lens at t=0mins and 0 DI in PBS. As time increases, DI on lens decreases (down to 
8.7%) (Figure 9a) and the DI in PBS increases (up to 0.034). An initial burst release between 
t=0mins and t=10mins (100% to 43% DI on lens) was exhibited which gradually plateaued 
after t=6 hours (9.79% DI on lens). Data collated from UV spectroscopy supported data using 
fluorescence microscopy; initial burst release of probe into PBS from 0 to 0.0064 within the 
first 10 mins of exposure which then gradually increased to 0.034 after 24 hrs.  For PNIPAM 
coated lens, a similar release profile was observed as with PVP; initial burst release followed 
by sustained release. Figure 9bi shows fluorescence images of each contact lens after 
removal from PBS and Figure 9bii shows the release profiles of Rhodamine B from the lens 
and into PBS.  DI on the lens decreases rapidly within 10 minutes (65.5% of probe was 
released) and the profile of release into PBS shows a sudden initial increase (from 0 to 0.01) 
within 10 minutes with subsequent gradual increase after 1 hour (0.016) to 24 hrs (0.047). 
With respect to the composite coated lenses an initial burst release with subsequent 
sustained release was observed with approximately 50% of the probe being released into 
the media and 50% remaining on the lens (Figure 9cii). After 6 hours, 71% of the dye had 
been released from the polymeric coatings and following the 24 hr mark, 89% of the probe 
had been released into PBS. The sustained release of Rhodamine B was exhibited from 10 
mins (0.07667; absorbance in PBS) to 24 hours (0.0426).   
Release kinetics 
To determine which type of release mechanism was prominent in this study, data from in 
vitro release of TM was fitted to various kinetic models to obtain graphical plots. The 
linearity of graphs was demonstrated by the regression co-efficient, R2 (Table 2); the higher 
the R
2
 value, the more linear the graph, the better the correlation between the variables.  
Drug release following zero-order kinetics demonstrates a release independent to the drug 
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concentration whilst first-order kinetics indicate the release of drug is concentration 
dependent (Table 2)  
 In order to determine if the release of TM was zero order, the cumulative percentage 
release of TM was plotted against time. For analysis of first order kinetics, log cumulative 
percentage of TM release was plotted as a function of time.  
Hixson-Cromwell cube root law is describes the release of drug due to change in particle 
surface area and diameter[36], where the cube root of percentage of drug remaining in the 
matrix is plotted versus time. 
The Higuchi model describes drug dissolution from various types of modified release from 
polymeric matrices. The model was originally intended for planar systems but evolved to 
extend to different geometries and porous matrices. The Higuchi model has been 
generalised to yield the simplified Higuchi Model [37].      
The Higuchi model is based on several hypotheses; i) initial drug concentration in the matrix 
is much higher than drug solubility; ii) drug diffusion is only in one plane; iii) drug particles 
are much smaller than the system matrix; iv) the matrix swelling and dissolution is 
negligible; v) drug diffusivity is constant; vi) perfect sink conditions in release environment 
are reached. The cumulative drug release of TM from all three samples was plotted as 
function of square root of time.  
The Korsmeyer-Peppas model was devised to explain the type of diffusive mechanism from 
polymeric matrix. Equation 3 shows the Korsmeyer-Peppas model;  
 
      


= 		     (Eqn.3 ) 
Where Mt/M∞ is the proportion of drug released at time, t; k is the release rate constant 
and n is the release exponent; the factor that determines the mechanism of drug release.  
Equation 4 shows how to derive the release exponent.  
                   	
                                          		log  × 100	 =  log 	 ×	 log                           (Eqn. 4) 
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The Korsmeyer-Peppas model is pragmatic when there are multiple possible release 
mechanisms.  For spherical matrices, various n values depict specific release mechanisms; 
n≤0.45 corresponds to quasi-Fickian drug transport, n=0.5 shows Fickian diffusion 
(molecular diffusion of drug due to a chemical potential gradient) , 0.45<n<0.89 relates a 
Non- Fickian diffusion mechanism, n=0.89 relates to the case II transport with n>0.89 
corresponds to the super case II transport[38] (drug transport mechanism associated with 
stresses and state transition in hydrophilic glassy polymers which swell in water and other 
biological fluids)[39].  Log cumulative release (%) was plotted as a function of log t; here 
only the first 60% was fitted to the Korsmeyer-Peppas model with resulting parameters 
collated from the model given in Table 3.  
All three formulations showed a poor fit for zero order and first order release kinetics, 
confirmed by low r2 values (Table 2). Results from the Hixson Cromwell model indicate the 
release of TM was not limited by dissolution but by the transport of drug through the 
polymeric matrix. Adequate linearity across all 3 TM loaded polymeric samples (F1, F2 and 
F3) were observed with the Higuchi Model (Table 2); suggesting TM release is a diffusive 
mechanism, in particular it is likely to be quasi-Fickian Diffusion. This is mirrored in the 
coefficient of determination (R
2
) of 0.5073, 0.6227 and 0.5021 for F1, F2 and F3 atomised 
formulations, respectively. Data collated from the Korsmeyer-Peppas model is shown in 
Table 3. For F1, F2 and F3, the n values were 0.1588, 0.1964 and 0.4921, respectively, which 
also indicate quasi-Fickian transport dominated the release of TM in PBS from polymeric 
nano-structures. Therefore the release mechanism of TM here was diffusion dominated 
[38,39].  
Biological Evaluation of TM-Loaded Nanoparticles  
The BCOP test is an organotypic assay utilised to assess the irritancy of test materials based 
on how corneal opacity and permeability is affected. An undamaged cornea is a clear 
structure which acts as a protective barrier which enables the cornea to remain 
impermeable to a large array of materials including sodium fluorescein dye. Hence, any 
damage to the cornea following treatment with test substances can be associated with said 
substances. 
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Figures 10a-c illustrates the response of bovine cornea opacity to TM-loaded nano-
structures alongside controls. Visual observation of the cornea confirms normal saline, the 
concurrent negative control, shows no damage to the cornea. There is also no change in the 
opacity of the cornea. In contrast, for the positive control, NaOH, unmistakable opacification 
can be detected; indicating the most severe damage to the cornea. Application of NaOH to 
the cornea results in interactions with corneal cell membranes. Subsequently, fatty acids in 
these cells undergo saponification; compromising not only the tight junctions between the 
corneal epithelial cells but the whole epithelium layer [40]; increasing the permeability of 
the cornea to the fluorescein dye. Clear visual evidence under a cobalt blue filter (465-
490nm) indicates that the fluorescein dye has permeated through the corneal layers in 
NaOH-treated cornea as seen in Figure 10h).  The mild positive control (acetone) exhibited a 
faint cloudy region, suggesting acetone to be a mild irritant to the eye. Acetone causes 
partial injury to epithelial cells as a result of lipid solvent interaction properties which can 
irritate mucosal membranes; ultimately resulting in eye irritation; demonstrated under a 
cobalt light filter as slight fluorescence (Figure 10i). The bovine cornea treated with normal 
saline exhibited no fluorescence, showing the dye had not permeated the cornea; 
highlighting the integrity of the cornea was not compromised. Similar results were yielded 
from TM-loaded ocular lenses; showing F1, F2 and F3 did not damage the cornea and are 
therefore biocompatible formulations for ocular device coating (Figures 10j-l).  
Ex vivo corneal permeation of TM 
Ex vivo permeation studies can provide an insight to how the electrically atomised 
formulations release drug and how the active permeates or penetrates the targeting tissue. 
TM permeation from atomised nano-structures was measured using freshly excised bovine 
corneas (figure 1e). Various parameters (steady state flux (Jss), apparent permeation 
coefficient (Papp)) were derived from this ex vivo study. Figure 11 shows the ex vivo 
permeation of TM over time whilst Table 4 shows the steady state flux and Papp values for all 
three atomised formulations. Statistical analysis (one way ANOVA) was conducted to report 
the statistical significance between the three formulations. The results showed a significant 
difference in ex vivo permeation between all three formulations (F (3,28)=3.340, p=0.033) 
with regards to the quantity of TM permeating through the excised cornea. The permeation 
rate of TM from F3 formulation was the highest (Jss=4.431µg.cm
-2.h-1; Papp = 0.9334cm.h
-1) 
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and was the lowest F1 (Jss=0.86977 µg/cm
2/h; Papp = 0.2827cm/h
-1). This difference is due to 
the combination of rapidly dissolving polymer (PVP) and thermosensitive, slowly dissolving 
polymer (PNIPAM) allowing the facilitation of TM corneal drug delivery. Based on a study by 
Moosa the in vivo effect on TM release from ocular inserts, marketing eye drops 
demonstrated Papp of 1.7x10
-4 cm.min-1 and Jss = 0.00052 mg.cm
-2.min-1 in rabbit eyes. The 
values are contrastingly higher that those derived in this study suggesting atomised (coated) 
lenses could lead to a reduction in frequent dosing and medicated applications. This 
reduction, in turn, has potential to minimise risk of ocular toxicity as a result of lowered 
systemic drug absorption [41]. Furthermore, such systems provide greater potential for 
patient compliance.  
Conclusion 
A variety of fibrous polymeric matrices incorporating TM were developed as on demand 
ocular lens coatings exhibiting sustained release of the glaucoma drug. Detailed analysis 
confirmed the viability of lens coatings. The novelty of combining an on demand EHDA 
engineering process for drug delivery via stabilised contact lens formulation has not yet 
been explored in great depth, and the current work demonstrates exciting possibilities. 
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 Tables and Figures Captions 
Tables 
Table1. Formulated sample composition and their loading efficiency. Polymer 
concentrations were 5% w/v and timolol maleate concentration 5% w/w of the polymer.  
[PVP: polyvinylpyrrolidone, PNIPAM: poly (N-isopropylacrylamide), TM: timolol maleate] 
Table 2. Kinetic models for timolol maleate release expressed by regression coefficient, R
2
. * 
Where Ct is the amount of drug released at time t, C0 is the initial amount of drug in release 
medium and k0 is the zero-order rate constant. ** Where C0 is the initial concentration of 
drug in the formulation, C indicates unreleased drug in formulation and K is the first order 
release constant. *** Where Mt is the quantity of cumulative drug released at time t, and kH 
is the Higuchi constant.  
Table 3. Korsmeyer-Peppas model parameters for timolol maleate release 
Table 4. Summary of parameters derived from ex-vivo release studies 
Figures 
Figure 1. (a) EHDA set-up (b) and (c) close-up lens substrate (d) diagrammatic presentation 
(e) Preparation of bovine cornea for ex-vivo drug release  
Figure 2. Flow of liquid under an electrical field using a single conductive needle under a) no 
flow, b) dripping mode. Stable cone jet formation when spraying c) F1, d) F2 and e) F3  
Jetting mode-map profiles for f) F1, g) F2 and h) F3 
Figure 3. a) Digital images of an uncoated lens, b) thin coated lens, c) densely coated lens,  
optical micrographs showing electrically atomised coatings of d) F1, e) F2 and f) F3. Electron 
micrographs of coatings at 5k magnification g) F1, h) F2 and i) F3 respectively and at 50k 
magnification j) F1, k) F2 and l) F3 respectively. Probe encapsulation m) fluorescence of PVP-
Rhodamine B, n) fluorescence of Rhodamine B-loaded PNIPAM nano-structures and o) 
Rhodamine B- composite polymer 
Figure 4. Particle size distribution of polymeric particles 
Figure 5.  Thermal analysis of atomised coatings a) DSC thermograms of raw materials and 
atomised samples. b) TGA thermograms for i) raw materials and ii) electrically atomised 
samples. 
Figure 6. FTIR spectra for raw materials and atomised structures. 
Figure 7. Contact angle analysis. Digital images taken during contact angle measurements 
over time for a) F1 samples, b) F2 samples, c) F3 samples at i) 0 seconds, ii) 30 seconds, iii) 
10 minutes and iv) 30 minutes, d) Contact Angle analysis over time for F1, F2 and F3. 
Figure 8. In vitro cumulative drug release (%) from various polymeric nano-structures. 
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Figure 9. a) PVP i) fluorescence images of dye-loaded F1 NPs coating on lenses. ii) Profile of 
dye* Intensity on lens at various time increments and dye* Intensity in PBS as a function of 
time , b) PNIPAM i) fluorescence images of dye-loaded F2 NPs coating on lens, ii) profile of 
dye* intensity of lens (vs. time increments) and dye* intensity in PBS as function of time.  
Figure 10. BCOP results of freshly excised bovine cornea. Digital images of treated cornea: a) 
negative control, b) positive control, c) slightly positive control, d) F1, e) F2 and f) F3 and  
fluorescence images under cobalt blue filter g) negative control, h) positive control, i) 
slightly positive control, j) F1, k) F2 and l) F3 
Figure 11. Ex vivo cumulative drug amount (µg) permeated across excised bovine cornea.  
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Tables  
Table 1 
Formulation Composition Loading Efficiency (%) 
F1 PVP , TM 64.63 
F2 PNIPAM, TM 79.8 
F3 PVP, PNIPAM, TM 99.7 
 
 
Table 2 
 
 
 
Table 3 
 
 
 
 
 
 
 
Formulation 
∗  =  +	"  
Zero-order 
∗∗ #$% = #$% −	' (. * *⁄  
First-order 
, 
-
* −	,
-
* = " 
Hixson-Cromwell 
∗∗∗. = "/√ 
Higuchi 
F1 0.1826 0.2092 0.0596 0.5073 
F2 0.3376 0.2217 0.1377 0.6227 
F3 0.2355 0.1604 0.0912 0.5021 
Formulation R
2
 n 
F1 0.8107 0.1588 
F2 0.7967 0.4921 
F3 0.6932 0.1964 
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Table 4 
 
 
 F1 F2 F3 
Sample Weight (mg) 1.33±0.058 4.10±0.70 1.63±0.58 
% Permeated / 
Surface area (%/cm²) 
after 24 hours 
60.13±5.51 47.70±5.07 90.11±8.95 
Steady State Flux 
(µg/cm²/min) 
0.017±0.0038 0.020±0.00081 0.057±0.017 
Apparent Permeability 
Coefficient (cm²/min) 
0.0055±0.0012 0.0052±0.00021 0.012±0.0038 
 
*Values presented are mean± standard deviation 
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Figure 10 
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